Cohen Fred E 4
4 · Intellia Therapeutics, Inc. · Filed Jun 10, 2026
Research Summary
AI-generated summary of this filing
Intellia (NTLA) Director Fred E. Cohen Receives 22,500-Share Award
What Happened
Fred E. Cohen, a director of Intellia Therapeutics, was awarded equity on June 9, 2026: 9,200 restricted stock units (RSUs) and a derivative award covering 13,300 shares (total potential 22,500 shares). Both grants were reported at $0.00 per share (no cash paid by Cohen). These are grants/awards (transaction code A), not open-market purchases or sales.
Key Details
- Transaction date: 2026-06-09; Form 4 filed 2026-06-10 (appears timely).
- Grants reported: 9,200 RSUs (acquired) and 13,300 derivative award units (acquired) at $0.00 per share.
- Post-transaction holdings: not specified in the provided filing summary.
- Footnotes:
- F1 — the 9,200 units are RSUs representing a contingent right to receive one share per unit.
- F2 — the 13,300-share derivative/option vests in full on the earlier of (a) the first anniversary of the grant or (b) the date of the next annual meeting of stockholders.
- No 10b5-1 plan, tax withholding, or immediate sale noted in the filing.
Context
These awards are standard director compensation and are not purchases (which some investors view as a stronger bullish signal). The derivative award is not an exercise—it’s a grant that vests per the schedule in F2; if/when vested and exercised or converted to shares, further filings would report those transactions.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-09+9,200→ 216,653 total - Award
Stock Option (right to buy)
[F2]2026-06-09+13,300→ 13,300 totalExercise: $12.89Exp: 2036-06-08→ Common Stock (13,300 underlying)
Footnotes (2)
- [F1]Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
- [F2]This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.